Coreline Soft Chosen as Exclusive AI Partner for France’s Lung Cancer Screening Pilot

Coreline Soft, a global leader in AI-powered chest diagnostics, has been selected as the exclusive artificial intelligence provider for IMPULSION, France’s national lung cancer screening pilot study. The initiative, sponsored by AP-HP (Paris Greater Hospital–France) and funded by INCa (Institut National du Cancer), is co-led by Professor Marie-Pierre Revel of AP-HP and Professor Sébastien Couraud of HCL (Hospices Civils de Lyon). Backed by €6 million in funding, the project will launch across more than 100 centers in France, supporting AI integration, hospital operations, physician training, patient recruitment, and CT imaging.

As part of IMPULSION, Coreline Soft will establish a nationwide AI supply system using local cloud infrastructure. Working with the French Society of Radiology (SFR), the company will also provide training programs for participating physicians focused on lung cancer screening and nodule management, leveraging AI tools to enhance detection and clinical workflows. The project aims to assess the conditions for implementing a full-scale national lung cancer screening program, with Coreline’s AVIEW platform serving as a key technology.

Following its CE MDR Class IIb certification in 2024, Coreline Soft has strengthened its European footprint through participation in several national screening initiatives, including Germany’s HANSE project, Italy’s RISP, and the Institute for Diagnostic Accuracy (iDNA). The company has also built a strong presence in North America through collaborations with Temple Health, Baylor College of Medicine, and 3DR Labs.